Biotech 2050 Podcast cover image

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Biotech 2050 Podcast

00:00

Differentiation and Competition in Biopharmaceuticals

This chapter examines the rise of 'Me Too' drugs within the GLP-1 market, focusing on how a lucrative environment prompts pharmaceutical companies to favor established biological strategies. The discussion also underscores the implications of increased competition, including price reduction and market saturation in specific drug classes.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app